Nitric Oxide Nasal Spray (NONS™)

SaNOtize’s first product, its antiviral Nitric Oxide Nasal Spray, has been shown to be effective against respiratory viruses, including all variants of COVID-19 tested during development.  The product has been used safely by hundreds of thousands of customers since launch.  In clinical studies, the Nasal Spray reduced the viral RNA load by more than 95% in COVID-19-positive participants within 24 hours of treatment, and by more than 99% within 72 hours.

The Nasal Spray is currently available as VirX™ or as enovid™, approved/registered as a medical device in Israel, Germany, South Africa, and several Asian countries. It is also available as FabiSpray in India as a prescription drug for the treatment of COVID-19 in high-risk individuals. The approval of FabiSpray in India was the first ever regulatory approval for NO as an antimicrobial therapeutic.

The Nasal Spray is not yet approved for sale in Canada. VirX™ and enovid™ are identical formulations based on our NORS™ platform technology. They have the same active ingredients and mechanisms of action as those nasal therapeutics used in our clinical trials. 

In 2024, we intend to introduce a wellness nasal spray product in the United States under the brand name NOWONDER Nasal Spray.  This product will not be indicated to treat or prevent any disease.  No claims regarding the NOWONDER Nasal Spray have been reviewed by the US Food and Drug Administration.